32 - Reimbursing Paris-Lamar County Board of Health for certain Covid-19 related expensesItem No. 32
TO: Mayor & City Council
Grayson Path, City Manager
FROM: Gene Anderson, Finance Director
SUBJECT: CARES ACT -CORONAVIRUS RELIEF FUND
DATE: July 27, 2020
BACKGROUND: Congress passed the CARES ACT to provide needed resources to respond to
the coronavirus pandemic. The City of Paris has been allocated up to $1,393,150 for COVID-19
related expenses that occur between March 1, 2020 and December 30, 2020. The Act also allows
governmental entities to use their resources in support other governmental entities who are also
working to fight this virus.
STATUS OF ISSUE: The City has received a request from the Paris -Lamar County Health District
for financial assistance in two areas related to COVID-19. First, their eight clinical staff employees
who work on COVID-19 issues are working many extra hours beyond their regular duties on
contact tracing. In under four months they have logged 768 hours in such efforts at a cost of
$23,237. Between now and December 30`x', the health district estimates that it will need to spend
another $43,000 in this area. This would include hiring two temporary employees to assist with
the contact tracing. Second, Lamar County Commissioners have agreed to purchase 900 COVID-
19 testing kits at a cost of $36,900 from Abbott. Abbott will provide the Health District with a
Coronavirus testing machine that uses the latest molecular technology. The machine can provide
positive results in 5 minutes and negative results in 13 minutes. The Health District requests that
the City also cover the cost of 830 additional test kits which have a 2 year shelf life. The Health
Districts tests people who cannot otherwise afford to be tested.
Lamar County is also spending $500,000 of their CARES ACT funding for what amounts to a
mobile testing site. This includes tents, generators, air conditioning units, and trailers to haul
everything to the needed location.
BUDGET: In summary, the Paris -Lamar County Health District is requesting up to $100,000 from
the City's CARES funding to reimburse them for personnel costs incurred for contact tracing
(approximately $66,000) and for testing kits (approximately $34,000).
RECOMMENDATION: The City staff believes that this request is a proper use of the funding
provided under the CARES ACT and is of direct benefit to the citizens of Paris.
RESOLUTION NO.
A RESOLUTION OF THE CITY COUNCIL OF THE CITY OF PARIS, TEXAS
AUTHORIZING REIMBURSEMENT FROM CARES ACT FUNDING TO THE
PARIS-LAMAR COUNTY HEALTH DISTRICT FOR COVID-19 RELATED
EXPENSES; MAKING OTHER FINDINGS AND PROVISIONS RELATED TO
THE SUBJECT; AND DECLARING AN EFFECTIVE DATE.
WHEREAS, the City of Paris has been allocated up to $1,393,150 from federal CARES
Act funds for COVID-19 expenses incurred between March 1, 2020 and December 30, 2020;
and
WHEREAS, under the terms of such funding, governmental entities may use the funds
in support of other governmental entities who are also working to fight COVID-19; and
WHEREAS, the Paris -Lamar County Health District ("the District") is a governmental
entity formed through an interlocal cooperative agreement between the City and Lamar
County pursuant to the Local Public Health Reorganization Act, codified as Chapter 121 of
the Texas Health & Safety Code; and
WHEREAS, in the last 4 months, the District's eight clinical staff employees who work
on COVID-19 issues have worked 768 hours beyond their regular duties on contact tracing
at a cost of $23,237.00; and
WHEREAS, the District estimates that it will need to spend an additional $43,000.00
on COVID-19 related service, including hiring two temporary employees to assist in contract
tracing; and
WHEREAS, the Lamar County Commissioner's Court has agreed to purchase 900
COVID-19 testing kits at a cost of $36,900.00 from Abbott to be processed on a machine
supplied by Abbott and that uses the latest molecular technology; and
WHEREAS, the District is asking the City to reimburse it for the $23,237.00 cost of
overtime already incurred; for an additional 830 test kits at an approximate cost of
$34,000.00; and for reimbursement for additional overtime and staff expenses related to
COVID-19 contact tracing once incurred; and
WHEREAS, the City Council finds that it is in the best interest of the health and
welfare of the citizens of the city that such expenses be reimbursed through CARES Act
funding;
NOW, THEREFORE, BE IT RESOLVED BY THE CITY COUNCIL OF THE CITY OF
PARIS, TEXAS, THAT:
Section 1. The findings set out in the preamble to this resolution are hereby in all
things approved.
Section 2. That the City Council authorizes the expenditure of up to $100,000.00 to
reimburse the Paris -Lamar County Health District for overtime and staff resources expended
on COVID-19 related duties, in particular, contact tracing, and for the purchase of 830 COVID-
19 test kits.
Section 3. This resolution shall be effective immediately upon passage.
DULY PASSED AND APPROVED this 27th day of July, 2020.
Steven J. Clifford, M.D., Mayor
ATTEST:
Janice Ellis, City Clerk
APPROVED AS TO FORM:
Stephanie H. Harris, City Attorney
• Leading molecular point -of -care (POC) platform in
the United States, trusted by hospitals, physician
offices and urgent care facilities nationwide
• High-quality molecular technology targeting
COVI D-19 Rd Rp gene
• Emergency Use Authorization
(EUA) supports flexible near -patient
testing environments
• Sample types tested direct or in viral
transport media (VTM) include:
- Throat swab
- Nasal swab
- Nasopharyngeal swab
• ID NOW platform designed with POC in mind
____ _............ ._ ___.
ID NOW TM COVID-19
�,r e U
h ktfle as �)rt e s
S 1) E E I) e
nl?st dts �'r) ("),i'4 I, Lrt e s,,'
5-13
Timely results enable healthcare professionals to make MINS
appropriate and more efficient treatment and infection
control decisions.
ID NOW" COVID-19
�Ir E C H �I"',411 0 1. 0 G Y
�)o ocess
( .... . ... ......
V
0"
)l ..... . ..... ......
ORDER INFORMATION
in a variety of environments"
PRODUCTNAME
• Assay kit contains all necessary components
IDNOW-COVID-19
24 TEST
Izes l l
0 U� r",
�E di� I dlogy
CONTROL KIT
a �r'ii l I '�f[, U,
lv e
�f�' r, p r ov 'd r e
CPT
Cod e: 8 7 635
- Positive and negative control swabs
• Room -temperature storage
g
�t r �1�
C I.,� �1 a r l S
t S
I tl e
�if r a r [(,,
e i,,:'
EASE OF USE , & r�I p i, �,,e 'test
�)o ocess
• Designed for near -patient testing
ORDER INFORMATION
in a variety of environments"
PRODUCTNAME
• Assay kit contains all necessary components
IDNOW-COVID-19
24 TEST
for testing, including:
KIT
111. 1 . DNOW - COVID-19
- 24 tests
CONTROL KIT
- Swabs for sample collection
(12 POSITIVE, 12 NEGATIVE)
I 11 I - - .- -
- Pipettes
CPT
Cod e: 8 7 635
- Positive and negative control swabs
• Room -temperature storage
eliminates need for refrigeration
PRODUCTCODE
110�1# I I
190-080
(C) M 0 U U E 0 N F0, M AT
C N I" AC 1I" YO I,11 R U 0 C M A 1�1311, IB 0 TT 1 Z IE jj
S U,, ii TA V II,""' 0 F'Z,
V II S I A B U 4 u,'C,'1%, C 0 1,,Vi 0 CII
The ID NOW''"'
COVID-19 EUA has not been FDA cleared or approved. it has been authorized by the FDA under an emergency use
authorization for use by authorized laboratories and patient care settings. The test has been authorized only for the detection Of
nucleic acid frorn SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that
circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of
COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. 9 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
11D NOW''"'
COVID-1.9 detects positive results in as a little as 5 minutes, Negative results detected in 13 minutes.
**Please see ID NOW Instrument user manual for additional operating environment requirements.
1. Internal clinical data held on file.
CG 2020 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of Ell,
companies or their respective owners. Any photos displayed are for illustrative purposes only:
120006407-0103/20 Abbott